公开(公告)号：WO9962908A3

公开(公告)日：2000-03-30

申请号：PCT/US9912419

申请日：1999-06-03

Applicant: ABBOTT LAB

Inventor： STEWART ANDREW O ,  BOYD STEVEN A ,  ARENDSEN DAVID L ,  BHATIA PRAMILA ,  CONDROSKI KEVIN R ,  FREEMAN JENNIFER C ,  GUNAWARDANA INDRANI W ,  ZHU GUI-DONG ,  LARTEY KRAIG ,  MCCARTY CATHERINE M ,  MORT NICHOLAS A ,  PATEL MEENA V ,  STAEGER MICHAEL A ,  STOUT DAVID M

IPC: A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/519 ,  A61K31/5377 ,  A61P29/00 ,  C07D471/04 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505

CPC classification number: C07D471/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: Compounds having Formula (I) are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compouns of Formula (I), and methods of inhibiting/treating inflammatory diseases in a mammal.

Abstract translation: 具有式（I）的化合物可用于治疗炎症。 还公开了包含式（I）的化合物的药物组合物，以及哺乳动物抑制/治疗炎性疾病的方法。

公开(公告)号：SI1124804T1

公开(公告)日：2006-02-28

申请号：SI9930842

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: C07D237/00 ,  A61K31/00 ,  C07D405/00 ,  C07D409/00

公开(公告)号：AT302759T

公开(公告)日：2005-09-15

申请号：AT99953259

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：PL355418A1

公开(公告)日：2004-04-19

申请号：PL35541898

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：HK1041876A1

公开(公告)日：2002-07-26

申请号：HK02101207

申请日：2002-02-19

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06 ,  C07D ,  A61K

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：TR200101765T2

公开(公告)日：2002-02-21

申请号：TR200101765

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：BR9914858A

公开(公告)日：2002-02-05

申请号：BR9914858

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：BG105523A

公开(公告)日：2001-12-31

申请号：BG10552301

申请日：2001-05-19

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazoline compounds of formula which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX 2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COC-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marked non-steroidal anti-inflammatory drugs (NSAIDs). 55 claims

公开(公告)号：CA2390948A1

公开(公告)日：2000-12-14

申请号：CA2390948

申请日：1999-06-28

Applicant: ABBOTT LAB

Inventor： FREEMAN JENNIFER C ,  GUNAWARDANA INDRANI W ,  ARENDSEN DAVID L ,  STOUT DAVID M ,  LARTEY KRAIG ,  BHATIA PRAMILA ,  ZHU GUI-DONG ,  PATEL MEENA V ,  BOYD STEVEN A ,  STEWART ANDREW O ,  STAEGER MICHAEL A ,  MORT NICHOLAS A ,  CONDROSKI KEVIN R ,  MCCARTY CATHERINE M

IPC: C07D491/048 ,  A61K31/415 ,  A61K31/425 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505 ,  A61K31/519 ,  A61K31/5355 ,  A61P9/00 ,  A61P29/00 ,  A61P35/04 ,  A61P37/00 ,  C07D221/00 ,  C07D239/00 ,  C07D333/00 ,  C07D471/04 ,  C07D491/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: Compounds having formula (I) are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compounds of formula (I ), and methods of inhibiting/treating inflammatory diseases in a mammal.

公开(公告)号：CA2333770A1

公开(公告)日：1999-12-09

申请号：CA2333770

申请日：1999-06-03

Applicant: ABBOTT LAB

Inventor： PATEL MEENA V ,  MORT NICHOLAS A ,  ZHU GUI-DONG ,  GUNAWARDANA INDRANI W ,  ARENDSEN DAVID L ,  STEWART ANDREW O ,  BOYD STEVEN A ,  STAEGER MICHAEL A ,  MCCARTY CATHERINE M ,  LARTEY KRAIG ,  STOUT DAVID M ,  FREEMAN JENNIFER C ,  CONDROSKI KEVIN R ,  BHATIA PRAMILA ,  MELCHER LAURA M

IPC: A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/519 ,  A61K31/5377 ,  A61P29/00 ,  C07D471/04 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D221/00 ,  C07D235/00 ,  C07D237/00 ,  C07D239/00 ,  C07D263/00 ,  C07D277/00 ,  C07D307/00 ,  C07D333/00 ,  A61K31/44 ,  A61K31/50 ,  A61K31/505

Abstract: Compounds having Formula (I) are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compouns of Formula (I) , and methods of inhibiting/treating inflammatory diseases in a mammal.